title: Tacrolimus dosage requirements in living donor liver transplant recipients with small-for-size grafts.
abstract: OBJECTIVE
  To investigate the tacrolimus dosage requirements and blood concentrations in adult-to-adult right lobe living donor liver transplantation (AALDLT) recipients with small-for-size (SFS) grafts.
  
  
  METHODS
  During January 2007 and October 2008, a total of 54 cases of AALDLT with an observation period of 6 mo were enrolled in this study. The 54 patients were divided into two groups according to graft-recipient body weight ratio (GRBW): SFS grafts group (Group S, GRBW < 0.8%, n = 8) and non-SFS grafts group (Group N, GRBW > or = 0.8%, n = 46). Tacrolimus 12-hour blood levels and doses were recorded during weeks 1, 2, 3 and 4 and months 2, 3, 4, 5 and 6 in group S and group N. Meanwhile, acute rejection rates, liver and renal function test results, and the number of potentially interacting medications were determined at each interval in the two groups. A comparison of tacrolimus dosage requirements and blood levels were made weekly in the first month post-surgery, and monthly from months 2 to 6.
  
  
  RESULTS
  There were no differences in the demographic characteristics, acute rejection rates, liver and renal function test results, or the number of potentially interacting medications administered between the two groups. The tacrolimus dosage requirements in group S were significantly lower than group N at 2 wk (2.8 +/- 0.4 mg/d vs 3.6 +/- 0.7 mg/d, P = 0.006), 3 wk (2.9 +/- 0.7 mg/d vs 3.9 +/- 0.8 mg/d, P = 0.008), 4 wk (2.9 +/- 0.8 mg/d vs 3.9 +/- 1.0 mg/d, P = 0.023) and 2 mo (2.8 +/- 0.7 mg/d vs 3.8 +/- 1.1 mg/d, P = 0.033). Tacrolimus 12-h trough concentrations were similar between the two groups at all times except for 2 wk post-transplantation, when the concentrations were significantly greater in group S recipients than in group N recipients (11.3 +/- 4.8 ng/mL vs 7.0 +/- 3.8 ng/mL, P = 0.026).
  
  
  CONCLUSIONS
  SFS grafts recipients have significantly decreased tacrolimus dosage requirements compared with non-SFS grafts recipients in AALDLT during the first 2 mo post-surgery.
authors.affiliation: Department of Liver and Vascular Surgery, Center of Liver Transplantation, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.
authors.forename: Fei
authors.initials: F
authors.lastname: Liu
authors.forename: Ya
authors.initials: Y
authors.lastname: Li
authors.forename: Xiang
authors.initials: X
authors.lastname: Lan
authors.forename: Yong-Gang
authors.initials: YG
authors.lastname: Wei
authors.forename: Bo
authors.initials: B
authors.lastname: Li
authors.forename: Lv-Nan
authors.initials: LN
authors.lastname: Yan
authors.forename: Tian-Fu
authors.initials: TF
authors.lastname: Wen
authors.forename: Ji-Chun
authors.initials: JC
authors.lastname: Zhao
authors.forename: Ming-Qing
authors.initials: MQ
authors.lastname: Xu
authors.forename: Wen-Tao
authors.initials: WT
authors.lastname: Wang
authors.forename: Jia-Yin
authors.initials: JY
authors.lastname: Yang
mesh_terms: D000328:Adult; D000368:Aged; D001835:Body Weight; D005260:Female; D006085:Graft Survival / Q000187:drug effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D016031:Liver Transplantation; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D009929:Organ Size; D016559:Tacrolimus / Q000494:pharmacology*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; D016559:Tacrolimus
references.citation: Clin Pharmacokinet. 1995 Dec;29(6):404-30
references.pmid: 8787947
references.citation: Hepatology. 2000 Jul;32(1):49-55
references.pmid: 10869288
references.citation: Transplantation. 2000 Dec 27;70(12):1697-703
references.pmid: 11152099
references.citation: Clin Transplant. 2003 Oct;17(5):412-6
references.pmid: 14703922
references.citation: Clin Transplant. 2002 Apr;16(2):102-6
references.pmid: 11966779
references.citation: Mol Pharmacol. 1993 Oct;44(4):707-15
references.pmid: 8232220
references.citation: Clin Transplant. 2004 Apr;18(2):124-9
references.pmid: 15016124
references.citation: Biol Pharm Bull. 2005 Sep;28(9):1805-8
references.pmid: 16141567
references.citation: Drug Metab Dispos. 2009 Apr;37(4):821-6
references.pmid: 19139162
references.citation: Pharmacotherapy. 2006 Aug;26(8):1069-77
references.pmid: 16863483
references.citation: Transplantation. 2000 Apr 15;69(7):1375-9
references.pmid: 10798757
references.citation: Transplant Proc. 1995 Feb;27(1):1108-10
references.pmid: 7533356
references.citation: Eur J Clin Pharmacol. 2001 Sep;57(6-7):479-84
references.pmid: 11699612
references.citation: Pharm Res. 1998 Oct;15(10):1609-13
references.pmid: 9794505
references.citation: Transplant Proc. 1991 Feb;23(1 Pt 2):1397-402
references.pmid: 1703340
references.citation: Surgery. 1990 Apr;107(4):417-27
references.pmid: 2181716
references.citation: Transplantation. 2002 Jan 15;73(1):159-60
references.pmid: 11793001
references.citation: Liver Transpl. 2004 Mar;10(3):374-8
references.pmid: 15004764
references.citation: Clin Transplant. 2006 Jul-Aug;20(4):443-9
references.pmid: 16842519
references.citation: Transplantation. 2003 Jul 15;76(1):5-10
references.pmid: 12865779
references.citation: J Pharmacol Exp Ther. 1998 Feb;284(2):760-7
references.pmid: 9454825
references.citation: Hepatology. 1989 Mar;9(3):393-7
references.pmid: 2920995
references.citation: Liver Transpl. 2002 Mar;8(3):219-23
references.pmid: 11910566
references.citation: Hepatogastroenterology. 2007 Oct-Nov;54(79):2078-83
references.pmid: 18251163
references.citation: Transplantation. 2008 Feb 27;85(4):554-60
references.pmid: 18347534
references.citation: Drug Metab Dispos. 1988 Jul-Aug;16(4):582-9
references.pmid: 2903027
references.citation: Transpl Int. 2002 Jul;15(7):355-60
references.pmid: 12122512
references.citation: Transpl Int. 2003 Nov;16(11):814-9
references.pmid: 12879228